rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

TGEN - Targeted Genetics

18 Posts
| Omlaag ↓
  2. Bel-chin 17 maart 2006 23:04

    • Bel-chin

      Lid sinds: 23 mrt 2005

      Laatste bezoek: 06 jun 2024

    • Aanbevelingen

      Ontvangen: 2

      Gegeven: 6

    •    Aantal posts: 188

    www.knobias.com/individual/public/new... c88866e3e38dadeb294cb5502857146c6c3c2ce7a7

    TGEN: FDA Approves Acceleration of Trial for Arthritis

    Thursday , March 16, 2006 08:47 ET

    Targeted Genetics Corporation (TGEN) announced that it has received approval from the FDA to amend the clinical protocol of its ongoing Phase I trial of tgAAC94 in patients with inflammatory arthritis. The protocol now includes a higher dose and increases the number of patients targeted for enrollment from 40 to 120. Under the amended protocol, the study is now designated a Phase I/II trial.
  5. [verwijderd] 7 november 2006 18:36

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Deze waren we blijkbaar ook vergeten ...+40%

    Targeted Genetics Shares Surge As Debt to Biogen Idec Restructured Through Stock Deal

    SEATTLE (AP) -- Shares of Targeted Genetics Corp. jumped Tuesday after the biotech drug developer restructured its debt with its largest shareholder, Biogen Idec Inc., through a stock deal.
    Targeted Genetics shares surged 96 cents, or 44.7 percent, to $3.11 in midday trading on the Nasdaq at about 24 times their average volume. Shares have traded between $1.71 and $6.90 over the past 52 weeks.

    Under an amended agreement, Biogen Idec agreed to take 1 million common shares of Targeted Genetics for $5.7 million of debt against the $8.2 million owed. The stock acquisition increases Biogen's ownership of the company to 19.9 percent.

    Biogen Idec, Cambridge, Mass., currently owns about 1.17 million of Targeted Genetics' approximately 9.9 shares outstanding.

    Targeted Genetics will pay Biogen $500,000 immediately and pay off the remaining $2 million under a new repayment schedule.

    Biogen Idec shares fell 3 cents to $48.38 on the Nasdaq.

    biz.yahoo.com/ap/061107/targeted_gene...
  15. [verwijderd] 27 november 2006 18:22

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Tja, er zitten af en toe leuke stijgingen tussen daar over de plas.

    CNLG staat bijna 200% in de plus (opende op 1,30 nu 3,90) Geen nieuws te zien.
  19. [verwijderd] 12 februari 2007 15:57

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Targeted Genetics Provides Inflammatory Arthritis Clinical Trial Update
    Monday February 12, 7:30 am ET

    Results Continue to Show Evidence for Sustained Improvement in Signs and Symptoms of Disease

    SEATTLE, WA--(MARKET WIRE)--Feb 12, 2007 -- Targeted Genetics Corporation (NasdaqCM:TGEN - News) provides an update today on its ongoing Phase I/II trial of tgAAC94 in patients with inflammatory arthritis. tgAAC94 is an investigational therapeutic designed to inhibit the activity of tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation. The data reported today support the safety and tolerability of a single and repeat intra-articular injections of tgAAC94 to affected joints at doses up to 1x10(13) DNase Resistant Particles per milli-liter (DRP/mL) of joint fluid in subjects with and without systemic TNF-alpha antagonists. The data also continue to suggest that treatment with tgAAC94 may lead to improvements in signs and symptoms of arthritis in injected joints.
    ADVERTISEMENT


    Interim analysis of the first three cohorts (n=61) indicate reduction of tenderness and swelling of the injected joint after tgAAC94 administration. The subjects, approximately half of whom were on systemic TNF-alpha antagonists, received an injection of blinded study drug into the knee, ankle, wrist, MCP or elbow. Thirty-nine subjects have received a second injection of open-label tgAAC94. Enrollment is ongoing and the effect of treatment and its duration continues to be evaluated.

    As previously presented at the American College of Rheumatology Annual Scientific meeting in November 2006, among the first 41 subjects randomized to the two lower doses of tgAAC94 or placebo, 7 of 10 subjects (70%) who received placebo qualified for open label tgAAC94 prior to 30 weeks, in contrast to 16 of 31 subjects (52%) who received tgAAC94. The median time to second injection was 120, 129 and 145 days for subjects who received placebo, tgAAC94 1x10(11) DRP/mL and tgAAC94 1x10(12) DRP/mL, respectively.

    "The data evaluated thus far are encouraging and we are very pleased that positive treatment response trends continue," said H. Stewart Parker, President and CEO of Targeted Genetics. "We are currently on track to complete enrollment of all 120 subjects in the study in the next few months, and plan to present additional interim data at multiple scientific venues during 2007."

    Deze ook maar weer naar boven halen, laatste tijd aardig terug gezakt..
18 Posts
|Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.120
AB InBev 2 5.538
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.177
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.859
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.840
Aedifica 3 926
Aegon 3.258 323.075
AFC Ajax 538 7.089
Affimed NV 2 6.305
ageas 5.844 109.905
Agfa-Gevaert 14 2.063
Ahold 3.538 74.353
Air France - KLM 1.025 35.293
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.050
Alfen 16 25.282
Allfunds Group 4 1.517
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 421
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.915
AMG 971 134.362
AMS 3 73
Amsterdam Commodities 305 6.745
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 496
Antonov 22.632 153.605
Aperam 92 15.059
Apollo Alternative Assets 1 17
Apple 5 386
Arcadis 252 8.806
Arcelor Mittal 2.034 320.988
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.355
Aroundtown SA 1 221
Arrowhead Research 5 9.751
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.614
ASML 1.766 110.178
ASR Nederland 21 4.512
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.940
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.449